Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HAEMONETICS CORPHAE · Entity 3953 | Director · President & CEO | May 15, 2026 | May 19, 2026 |
| Sotera Health CoSHC · Entity 3869 | Director | May 22, 2026 | May 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HAEMONETICS CORP
Report date May 15, 2026 · Filed May 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 444,704 |
Last balance in matching sequence
After 2026-05-15 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-05-15 · Tax withholding · Disposed 9,681 · Balance 366,360 F1: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2: This number includes unvested RSUs previously reported as well as 497 shares purchased by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026. Row 2 · 2026-05-15 · Grant · Acquired 78,344 · Balance 444,704 F3: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant. F4: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F2: This number includes unvested RSUs previously reported as well as 497 shares purchased by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
F2: This number includes unvested RSUs previously reported as well as 497 shares purchased by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026.
F3: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.
F4: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Sotera Health Co
Report date May 22, 2026 · Filed May 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par value per share ("Common Stock")SEC Table I · non-derivative | Direct | 34,102 |
Reported balance
After 2026-05-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-22 · Grant · Acquired 14,970 · Balance 34,102 F1: These securities consist of 14,970 restricted stock units ("RSUs") that were granted on May 22, 2026, pursuant to the terms of an RSU agreement under the Sotera Health Company 2020 Omnibus Incenctive Plan. Each RSU represents the Reporting Person's right to receive one share of Common Stock, subject to vesting conditions. The RSUs will vest in full on the earlier of (i) the first anniversary of the date of grant, or (ii) the date immediately prior to the Issuer's next regular annual shareholders meeting, subject to the Reporting Person's continued service as a non-employee director of the Issuer through such date. F2: These securities consist of 14,970 RSUs and 19,132 shares of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities consist of 14,970 restricted stock units ("RSUs") that were granted on May 22, 2026, pursuant to the terms of an RSU agreement under the Sotera Health Company 2020 Omnibus Incenctive Plan. Each RSU represents the Reporting Person's right to receive one share of Common Stock, subject to vesting conditions. The RSUs will vest in full on the earlier of (i) the first anniversary of the date of grant, or (ii) the date immediately prior to the Issuer's next regular annual shareholders meeting, subject to the Reporting Person's continued service as a non-employee director of the Issuer through such date.
F2: These securities consist of 14,970 RSUs and 19,132 shares of Common Stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 22, 2026 Filed May 27, 2026 21:21 UTC | Sotera Health Co SHC · Entity 3869 | GrantCommon Stock, $0.01 par value per share ("Common Stock") | 14,970 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-242181 · ownership.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,102 F1 · shares: These securities consist of 14,970 restricted stock units ("RSUs") that were granted on May 22, 2026, pursuant to the terms of an RSU agreement under the Sotera Health Company 2020 Omnibus Incenctive Plan. Each RSU represents the Reporting Person's right to receive one share of Common Stock, subject to vesting conditions. The RSUs will vest in full on the earlier of (i) the first anniversary of the date of grant, or (ii) the date immediately prior to the Issuer's next regular annual shareholders meeting, subject to the Reporting Person's continued service as a non-employee director of the Issuer through such date. F2 · balance_after: These securities consist of 14,970 RSUs and 19,132 shares of Common Stock. Read SEC document |
| May 15, 2026 Filed May 19, 2026 21:28 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 78,344 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000313143-26-000042 · form4.xml · nonDerivative · entry 2 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 444,704 F3 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant. F4 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F2 · balance_after: This number includes unvested RSUs previously reported as well as 497 shares purchased by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026. Read SEC document |
| May 15, 2026 Filed May 19, 2026 21:28 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 9,681 | $56.29 | $544,943.49 |
DisclosureSEC source: 0000313143-26-000042 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 366,360 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported as well as 497 shares purchased by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:41 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 26,234 | $69.38 | $1,820,114.92 |
DisclosureSEC source: 0001127602-25-016532 · form4.xml · nonDerivative · entry 2 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,544 F3 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:41 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 66,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-016532 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 401,778 F1 · shares: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 16, 2022, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 16, 2022 to May 15, 2025, as certified by the Compensation Committee of the Board of Directors on May 30, 2025. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| May 22, 2025 Filed May 27, 2025 20:36 UTC | Sotera Health Co SHC · Entity 3869 | GrantCommon Stock, $0.01 par value per share ("Common Stock") | 19,132 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-077776 · ownership.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,132 F1 · shares: These securities consist of 19,132 restricted stock units ("RSUs") that were granted on May 22, 2025, pursuant to the terms of an RSU agreement under the Sotera Health Company 2020 Omnibus Incentive Plan. Each RSU represents the Reporting Person's right to receive one share of Common Stock, subject to vesting conditions. The RSUs will vest in full on the earlier of (i) the first anniversary of the date of grant, or (ii) the date immediately prior to the Issuer's next regular annual shareholders meeting, subject to the Reporting Person's continued service as a non-employee director of the Issuer through such date. Read SEC document |
| May 16, 2025 Filed May 19, 2025 21:05 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 7,089 | $70.31 | $498,427.59 |
DisclosureSEC source: 0001127602-25-014933 · form4.xml · nonDerivative · entry 2 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 313,707 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported as well as 349 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2025. Read SEC document |
| May 16, 2025 Filed May 20, 2025 21:10 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 46,342 | $0.00 Strike: $70.31 | $0.00 |
DisclosureSEC source: 0001127602-25-015052 · form4.xml · derivative · entry 2 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,342 Underlying: Common Stock · 46,342 shares Expires 2032-05-16 F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 16, 2025 Filed May 20, 2025 21:10 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 21,405 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-015052 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 335,112 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 15, 2025 Filed May 19, 2025 21:05 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 2,391 | $69.38 | $165,887.58 |
DisclosureSEC source: 0001127602-25-014933 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 320,796 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported as well as 349 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2025. Read SEC document |
| August 29, 2024 Filed Sep 3, 2024 20:20 UTC | HAEMONETICS CORP HAE · Entity 3953 | OtherCommon Stock | 39,704 | $75.56 | $3,000,034.24 |
DisclosureSEC source: 0001127602-24-023305 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 322,838 F1 · shares: On August 29, 2024, in an asset substitution transaction, Mr. Simon transferred 39,704 shares of the Issuer's common stock to the Simon Family Irrevocable Trust for the benefit of the reporting person's children, in exchange for cash in the amount of $3,000,034, with the number of shares determined by averaging the high and low sales prices of the Issuer's common stock as reported by the New York Stock Exchange on August 29, 2024. The substitution was made in accordance with the terms of the trust, which has an independent trustee. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:15 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 104,516 | $0.00 Strike: $41.64 | $0.00 |
DisclosureSEC source: 0001127602-24-018160 · form4.xml · derivative · entry 3 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 104,516 shares Expires 2024-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an automatic exercise of options granted in 2017 and scheduled to expire after June 6, 2024, as reflected in this Form 4. F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:15 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 71,335 | $87.38 | $6,233,252.30 |
DisclosureSEC source: 0001127602-24-018160 · form4.xml · nonDerivative · entry 2 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 362,542 F3 · shares: Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:15 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 104,516 | $41.64 | $4,352,046.24 |
DisclosureSEC source: 0001127602-24-018160 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 433,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an automatic exercise of options granted in 2017 and scheduled to expire after June 6, 2024, as reflected in this Form 4. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| May 28, 2024 Filed May 29, 2024 21:31 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 41,736 | $95.73 | $3,995,387.28 |
DisclosureSEC source: 0001127602-24-016803 · form4.xml · nonDerivative · entry 2 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 329,361 F3 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| May 28, 2024 Filed May 29, 2024 21:31 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 106,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-016803 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 371,097 F1 · shares: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 18, 2021, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 18, 2021 to May 17, 2024, as certified by the Compensation Committee of the Board of Directors on May 26, 2024. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| May 17, 2024 Filed May 21, 2024 21:38 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 32,140 | $0.00 Strike: $95.73 | $0.00 |
DisclosureSEC source: 0001127602-24-016160 · form4.xml · derivative · entry 3 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,140 Underlying: Common Stock · 32,140 shares Expires 2031-05-17 F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 17, 2024 Filed May 21, 2024 21:38 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 14,624 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-016160 · form4.xml · nonDerivative · entry 2 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,035 F3 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. F4 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 17, 2024 Filed May 21, 2024 21:38 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 4,037 | $95.73 | $386,462.01 |
DisclosureSEC source: 0001127602-24-016160 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,411 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 16, 2024 Filed May 17, 2024 20:46 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 1,907 | $94.80 | $180,783.60 |
DisclosureSEC source: 0001127602-24-015854 · form4.xml · nonDerivative · entry 2 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 254,448 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported as well as 289 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2024. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:46 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 1,480 | $96.49 | $142,805.20 |
DisclosureSEC source: 0001127602-24-015854 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,355 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported as well as 289 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2024. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 20:44 UTC | HAEMONETICS CORP HAE · Entity 3953 | GiftCommon Stock | 38,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-009995 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257,546 F1 · kind: These securities were transferred by the reporting person as a gift without any consideration to the Simon Family 2020 Irrevocable Trust for the benefit of the reporting person's children, which trust has an independent trustee. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 20:17 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 196,746 | $0.00 Strike: $28.62 | $0.00 |
DisclosureSEC source: 0001127602-23-019619 · form4.xml · derivative · entry 3 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 196,746 shares Expires 2023-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an automatic exercise of options granted in 2016 and scheduled to expire after June 29, 2023, as reflected in this Form 4. F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 20:17 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 117,667 | $84.84 | $9,982,868.28 |
DisclosureSEC source: 0001127602-23-019619 · form4.xml · nonDerivative · entry 2 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 296,446 F3 · shares: Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 20:17 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 196,746 | $28.62 | $5,629,886.79 |
DisclosureSEC source: 0001127602-23-019619 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 414,113 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an automatic exercise of options granted in 2016 and scheduled to expire after June 29, 2023, as reflected in this Form 4. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| May 18, 2023 Filed May 19, 2023 20:32 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 3,839 | $83.34 | $319,942.26 |
DisclosureSEC source: 0001127602-23-016309 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,367 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| May 16, 2023 Filed May 17, 2023 20:25 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 1,586 | $89.21 | $141,487.06 |
DisclosureSEC source: 0001127602-23-015925 · form4.xml · nonDerivative · entry 2 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,206 F4 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:25 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 41,177 | $0.00 Strike: $89.16 | $0.00 |
DisclosureSEC source: 0001127602-23-015925 · form4.xml · derivative · entry 3 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,177 Underlying: Common Stock · 41,177 shares Expires 2030-05-15 F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:25 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 18,225 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-015925 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,792 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 12, 2023 Filed May 16, 2023 20:15 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 854 | $88.16 | $75,288.64 |
DisclosureSEC source: 0001127602-23-015735 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,567 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported as well as 297 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 28, 2023. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 21:40 UTC | HAEMONETICS CORP HAE · Entity 3953 | GiftCommon Stock | 8,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-025631 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,124 F1 · kind: These securities were transferred by the reporting person as a gift without any consideration to the Simon Family 2020 Irrevocable Trust for the benefit of the reporting person's children, which trust has an independent trustee. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 20:27 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 1,148 | $62.60 | $71,864.80 |
DisclosureSEC source: 0001127602-22-017539 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,724 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 19, 2022 Filed May 23, 2022 20:17 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 2,496 | $59.10 | $147,513.60 |
DisclosureSEC source: 0001127602-22-015375 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,872 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:26 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 60,891 | $0.00 Strike: $57.60 | $0.00 |
DisclosureSEC source: 0001127602-22-014951 · form4.xml · derivative · entry 3 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,891 Underlying: Common Stock · 60,891 shares Expires 2029-05-16 F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:26 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 26,041 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-014951 · form4.xml · nonDerivative · entry 2 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,368 F3 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F4 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F2 · balance_after: This number includes unvested RSUs previously reported as well as 353 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 29, 2022. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:26 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 832 | $56.10 | $46,675.20 |
DisclosureSEC source: 0001127602-22-014951 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,327 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported as well as 353 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 29, 2022. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 20:29 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 1,200 | $59.87 | $71,844.00 |
DisclosureSEC source: 0001127602-21-020048 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,806 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 20:27 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 2,715 | $55.09 | $149,569.35 |
DisclosureSEC source: 0001127602-21-019521 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,006 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 19, 2021 Filed May 20, 2021 21:55 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 1,024 | $55.19 | $56,514.56 |
DisclosureSEC source: 0001127602-21-017675 · form4.xml · nonDerivative · entry 2 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,721 F4 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 18, 2021 Filed May 20, 2021 21:55 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 71,733 | $0.00 Strike: $56.57 | $0.00 |
DisclosureSEC source: 0001127602-21-017675 · form4.xml · derivative · entry 3 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,733 Underlying: Common Stock · 71,733 shares Expires 2028-05-18 F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 18, 2021 Filed May 20, 2021 21:55 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 26,515 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-017675 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,745 F1 · kind: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 17, 2021 Filed May 18, 2021 22:14 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 956 | $55.97 | $53,507.32 |
DisclosureSEC source: 0001127602-21-017256 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,230 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported as well as 245 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2021. Read SEC document |
| December 10, 2020 Filed Dec 11, 2020 21:59 UTC | HAEMONETICS CORP HAE · Entity 3953 | GiftCommon Stock | 194,369 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-031192 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,941 F1 · kind: These securities were transferred by the reporting person as a gift without any consideration to the Simon Family 2020 Irrevocable Trust for the benefit of the reporting person's children, which trust has an independent trustee. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:20 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 5,084 | $87.79 | $446,324.36 |
DisclosureSEC source: 0001127602-20-020895 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,310 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 21:51 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 45,723 | $87.71 | $4,010,364.33 |
DisclosureSEC source: 0001127602-20-019787 · form4.xml · nonDerivative · entry 3 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,394 F4 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the PSUs reported above on June 12, 2020. This sale is mandated by the Issuer's election under its 2005 Long-Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the PSUs reported above on June 12, 2020. This sale is mandated by the Issuer's election under its 2005 Long-Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 21:51 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 1,294 | $89.29 | $115,541.26 |
DisclosureSEC source: 0001127602-20-019787 · form4.xml · nonDerivative · entry 2 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,117 F3 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 21:51 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 102,064 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-019787 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417,411 F1 · kind: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on June 6, 2017, based on the issuer's total shareholder return relative to that of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600 for the performance period from June 6, 2017 to June 5, 2020, as certified by the Compensation Committee of the Board of Directors on June 12, 2020. F1 · shares: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on June 6, 2017, based on the issuer's total shareholder return relative to that of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600 for the performance period from June 6, 2017 to June 5, 2020, as certified by the Compensation Committee of the Board of Directors on June 12, 2020. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 21:52 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 2,920 | $97.03 | $283,327.60 |
DisclosureSEC source: 0001127602-20-019374 · form4.xml · nonDerivative · entry 1 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,347 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 18, 2020 Filed May 19, 2020 23:06 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 49,105 | $0.00 Strike: $103.37 | $0.00 |
DisclosureSEC source: 0001127602-20-017282 · form4.xml · derivative · entry 3 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,105 Underlying: Common Stock · 49,105 shares Expires 2027-05-18 F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 18, 2020 Filed May 19, 2020 23:06 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 14,510 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-017282 · form4.xml · nonDerivative · entry 2 Simon, Christopher · CIK 0001674993 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,267 F3 · kind: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F3 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F4 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F2 · balance_after: This number includes unvested RSUs previously reported as well as 193 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.